We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inexpensive Diagnostic Device May Revolutionize Medical Care

By LabMedica International staff writers
Posted on 28 Feb 2017
A radically designed “lab on a chip” diagnostic device is expected to dramatically reduce the cost of isolating and characterizing rare cells and molecules, a process that is of critical importance in diagnosis of common lethal diseases such as malaria, tuberculosis, HIV, and cancer.

Point-of-care diagnostics in the developing world and resource-limited areas require numerous special design considerations to provide effective early detection of disease. More...
Of particular need for these contexts are diagnostic technologies featuring low costs, ease of use, and broad applicability. Investigators at Stanford University recently described a nanoparticle-inkjet-printable microfluidics-based platform that fulfilled these criteria and that is expected to significantly reduce the footprint, complexity, and cost of clinical diagnostics. This reusable 0.01 USD device is miniaturized to handle small sample volumes and can perform numerous analyses.

The device is a combination of microfluidics, electronics, and inkjet printing technology. It is in essence a two-part system: a clear silicone microfluidic chamber for housing cells resting on top of a reusable electronic strip. A regular inkjet printer was used to print the electronic strip onto a flexible sheet of polyester using commercially available conductive nanoparticle ink.

The device, which separates cells based on their size and intrinsic electrical properties, can perform label-free and rapid single-cell capture, efficient cellular manipulation, rare-cell isolation and selective analytical separation of biological species, sorting, concentration, positioning, enumeration, and characterization. The miniaturized format allows for small sample and reagent volumes. By keeping the electronics separate from microfluidic chips, the former can be reused and device lifetime is extended.

The process of manufacturing the device is significantly less expensive, time-consuming, and complex than traditional lab-on-a-chip platforms, requiring only an inkjet printer rather than skilled personnel and clean-room facilities. Production requires only about 20 minutes (versus up to weeks) and one US cent - an unprecedented cost in in clinical diagnostics.

“The genome project has changed the way an awful lot of medicine is done, and we want to continue that with all sorts of other technology that are just really inexpensive and accessible,” said senior author Dr. Ronald W. Davis, professor of biochemistry and genetics at Stanford University. “The motivation was really how to export technology and how to decrease the cost of things.”

A study describing the technology was published in the February 6, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.